Drug development firm “close” to commercialising skin cancer treatment
Manchester-based cancer treatment specialist Incanthera is “close” to commercialising its topical skin cancer technology, Sol.
The company’s lead product is a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers.
Incanthera said it has achieved proof of concept for Sol and has been progressing talks with two global cosmetic companies.
In addition, it said Sol has attracted the attention of two further companies and initial discussions in relation to the rights to Sol have recently started.
During the period the group also revealed an operating loss of £582,000.
Chairman Tim McCarthy said: “We have made excellent progress in our discussions on the commercial rights for Sol during this period and have recently initiated commercial discussions with two further companies.
“The conclusion of the right deal for commercialisation of Sol is of paramount importance for the future success of the Company and the whole team is engaged in delivering this for our shareholders.
“As we approach the end of 2021, I would like to thank our shareholders for their continuing support and our team for their hard work and dedication. We look forward to sharing further progress next year.”
CEO Simon Ward added: “The opportunities in front of us to progress discussions and expand the opportunities for our dermatology technologies means we close the year with confidence and optimism.”